October 14, 2020
Oncopeptides signs € 40 million loan agreement with the EIB
STOCKHOLM — October 14, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company has entered into a loan agreement with the European Inves...
Read more
Read more
October 13, 2020
Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer
The pre-defined disease control efficacy threshold in part 1 in the colorectal cancer cohort has been met
The colorectal expansion cohort has been opened for recruitment o...
Read more
Read more
October 12, 2020
Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
Financing to advance mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, and potential best-in-class therapy for AML patients
DUBLIN, Ireland – 12th Oc...
Read more
Read more
October 12, 2020
With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA
TOCKHOLM — October 12, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the Company has informed the European Medicines Agency, EMA, about its...
Read more
Read more
October 12, 2020
Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors
Oslo, 12 October 2020: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-tr...
Read more
Read more
October 9, 2020
Spruce Biosciences Announces Pricing of Upsized Initial Public Offering
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine di...
Read more
Read more
October 8, 2020
Nordic Nanovector publishes results of preclinical study demonstrating Betalutin® reverses tumour resistance to rituximab in NHL disease models
Oslo, Norway, 8 October 2020
Nordic Nanovector ASA (OSE: NANO) announces that its preclinical study investigating the ability of Betalutin® (177Lu-lilotomab satetraxe...
Read more
Read more
October 7, 2020
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer...
Read more
Read more
October 1, 2020
Oncopeptides initiates U.S. Expanded Access Program with melflufen in triple-class refractory multiple myeloma
STOCKHOLM — October 1, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) announced today that the open-label Expanded Access Program, sEAPort, for eligible U.S. pa...
Read more
Read more
October 1, 2020
Vicore Pharma announces completion of patient enrollment in the COVID-19 ATTRACT trial
Gothenburg, October 1, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announces ...
Read more
Read more